Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

SNMMI 2025 novel PSMA-targeting drug 177Lu-P17-088, metastatic castration-resistant prostate cancer (mCRPC), VISION and PSMAfore trials, PCWG3 guidelines.

Interdisciplinary GU Cancer Forum 2025 Combination Therapies in prostate cancer, active surveillance, GG1 prostate cancer, radical prostatectomy.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, between June 21 st and 24 th, 2025, was host to an Oncology Discovery and ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer oral abstract session and a presentation by Dr. Theodore DeWeese discussing a phase 3, randomized, placebo-controlled clinical ...

ASCO 2025 PSMA–positive biochemically recurrent prostate cancer, metastatic castration sensitive prostate cancer (mCSPC), mCSPC trials.

ASCO 2025 First PARP Inhibitor Combo to Show Benefit in mCSPC Johnson & Johnson's AKEEGA® (niraparib + abiraterone acetate) is the first PARP-based combination to demonstrate statistically significant ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...

Interdisciplinary GU Cancer Forum 2025, Emerging Data and Advances in Prostate cancer Screening, Prostate cancer, homologous recombination repair (HRR), metastatic castration-resistant prostate cancer ...

Interdisciplinary GU Cancer Forum 2025 Prostate Cancer, Artificial Intelligence in Molecular Targeted Imaging, ChatGPT by OpenAI, aPROMISE platform.